Regeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
Post navigation
Previous Post
Your AI Is Only as Good as Your Inputs